NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment

The heterogeneity of ALK tyrosine-kinase inhibitor (TKI) responses poses a puzzling question to clinicians. Different variants of ALK rearrangements might be one of the mechanisms explaining this phenomenon. Therefore, identifying specific fusion forms is crucial to clinical practice. This case repo...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Qi, Liu, Zhiguang, Huang, Yanhua, Qi, Chuang, Yin, Xiaowei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369846/
https://www.ncbi.nlm.nih.gov/pubmed/30799936
http://dx.doi.org/10.2147/OTT.S192367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369846/
https://www.ncbi.nlm.nih.gov/pubmed/30799936
http://dx.doi.org/10.2147/OTT.S192367

Ejemplares similares